CRISPR/Cas9 mediated gene modification combined with human iPSC technology provides a powerful tool for generating disease-specific models for drug discovery researchers.
Freedom to operate - simplified licencing structure, IP protection and path to scale
Isogenic control cells - unedited control available to remove challenge of background-related variability
Efficiency - fully integrated service including hiPSC gene editing, differentiation and manufacturing
Expertise - proven leaders in CRISPR gene editing and stem cell technologies
At Ncardia we employ state-of-the-art systems for the culture of high-quality hiPSC-derived cell lines. The combination of these systems with our proprietary differentiation protocols allows us to offer a fast and robust industrial-scale manufacturing of the hiPSC-derived cells of interest. Contact us to discuss your cells of interest.
Through a partnership with Horizon Discovery, CRISPR/Cas9 is used to engineer mutations into induced pluripotent stem cell lines, Cor.4U® or Pluricytes®. A range of custom modifications are available, including knockin, knockout and point mutations. Estimated timelines for generation of the edited clones is 4-6 months.
Differentiated terminal cell types are produced from Cor.4U® or Pluricyte® iPS cell lines. The cells are confirmed to be mycoplasma free, sterile, and basic characterization such as impedance and Troponin T measurement are performed. The estimated timeline for this component is 6-9 weeks, depending on the chosen iPSCs.
Our dedicated service team is always available for consultation. For custom phenotype investigation, we offer the possibility to secure research & development resources from Ncardia for selected projects. Additionally, the cell lines produced through the service are compatible with many Ncardia standard services and custom services can be developed upon request.